Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies

Citation
Hc. Maltezou et al., Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies, INT J ANT A, 18(4), 2001, pp. 383-386
Citations number
14
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Microbiology
Journal title
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
ISSN journal
0924-8579 → ACNP
Volume
18
Issue
4
Year of publication
2001
Pages
383 - 386
Database
ISI
SICI code
0924-8579(2001)18:4<383:COIWAF>2.0.ZU;2-W
Abstract
The efficacy and safety of isepamicin at 7.5 mg/kg i.v. q 12 h was prospect ively compared with that of amikacin at the same dose for the treatment of febrile neutropenic children with malignancies. Thirty-nine patients were e nrolled in the study 25 received isepamicin and 14 amikacin. Clinical and b acteriological response rates were 100%, for both groups. No adverse events occurred. Median peak serum levels were 19.7 mg/l for isepamicin and 19.20 mg/l for amikacin. Median trough serum levels were 0.72 mg/l for isepamici n and 0.68 mg/l for amikacin. It was concluded that isepamicin was as effec tive and safe as amikacin for the treatment of febrile neutropenic children with malignancies, and might be used in areas where resistance to other am inoglycosides is a problem. (C) 2001 Elsevier Science B.V. and Internationa l Society of Chemotherapy. All rights reserved.